Kintegral Advisory’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.2M | Hold |
52,394
| – | – | 1.07% | 20 |
|
|
2026
Q1 | $11.4M | Sell |
52,394
-2,323
| -4% | -$515K | 1.08% | 18 |
|
|
2025
Q4 | $12.5M | Sell |
54,717
-1,497
| -3% | -$341K | 1.06% | 17 |
|
|
2025
Q3 | $13M | Sell |
56,214
-251
| -0.4% | -$51.1K | 1.11% | 17 |
|
|
2025
Q2 | $10.5M | Sell |
56,465
-85
| -0.2% | -$15.8K | 0.95% | 19 |
|
|
2025
Q1 | $11.8M | Sell |
56,550
-190
| -0.3% | -$36.9K | 1.19% | 14 |
|
|
2024
Q4 | $10.1M | Sell |
56,740
-2,643
| -4% | -$486K | 0.95% | 20 |
|
|
2024
Q3 | $11.7M | Sell |
59,383
-778
| -1% | -$145K | 1.08% | 15 |
|
|
2024
Q2 | $10.3M | Buy |
60,161
+6,456
| +12% | +$1.07M | 0.99% | 16 |
|
|
2024
Q1 | $9.78M | Sell |
53,705
-167
| -0.3% | -$28.8K | 0.98% | 18 |
|
|
2023
Q4 | $8.35M | Sell |
53,872
-342
| -0.6% | -$49.9K | 0.92% | 22 |
|
|
2023
Q3 | $8.08M | Sell |
54,214
-32
| -0.1% | -$4.7K | 1% | 19 |
|
|
2023
Q2 | $7.31M | Hold |
54,246
| – | – | 0.87% | 23 |
|
|
2023
Q1 | $8.65M | Sell |
54,246
-2,914
| -5% | -$446K | 1.12% | 15 |
|
|
2022
Q4 | $9.24M | Buy |
57,160
+198
| +0.3% | +$30.4K | 1.22% | 14 |
|
|
2022
Q3 | $7.64M | Hold |
56,962
| – | – | 1.06% | 13 |
|
|
2022
Q2 | $8.72M | Buy |
56,962
+1,206
| +2% | +$184K | 1.13% | 13 |
|
|
2022
Q1 | $9.04M | Buy |
55,756
+1,247
| +2% | +$181K | 0.99% | 15 |
|
|
2021
Q4 | $7.38M | Hold |
54,509
| – | – | 0.76% | 26 |
|
|
2021
Q3 | $5.88M | Hold |
54,509
| – | – | 0.69% | 30 |
|
|
2021
Q2 | $6.14M | Hold |
54,509
| – | – | 0.73% | 28 |
|
|
2021
Q1 | $5.9M | Hold |
54,509
| – | – | 0.76% | 27 |
|
|
2020
Q4 | $5.84M | Hold |
54,509
| – | – | 0.79% | 26 |
|
|
2020
Q3 | $4.77M | Sell |
54,509
-1,754
| -3% | -$165K | 0.72% | 30 |
|
|
2020
Q2 | $5.52M | Buy |
56,263
+3,385
| +6% | +$298K | 0.89% | 23 |
|
|
2020
Q1 | $4.03M | Buy |
52,878
+5,916
| +13% | +$504K | 0.78% | 31 |
|
|
2019
Q4 | $4.16M | Hold |
46,962
| – | – | 0.76% | 31 |
|
|
2019
Q3 | $3.56M | Hold |
46,962
| – | – | 0.71% | 36 |
|
|
2019
Q2 | $3.42M | Hold |
46,962
| – | – | 0.69% | 35 |
|
|
2019
Q1 | $3.79M | Buy |
46,962
+26,317
| +127% | +$2.15M | 0.8% | 27 |
|
|
2018
Q4 | $1.9M | Buy |
+20,645
| New | +$1.82M | 0.56% | 45 |
|
Other funds holding ABBV
Kintegral Advisory's ABBV Position: Q2 2026 in Review
Kintegral Advisory held its AbbVie (ABBV) position steady in Q2 2026 at 52,394 shares worth $13.2M. The position accounts for 1.07% of the portfolio, ranked #20.
Kintegral Advisory first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Kintegral Advisory held 52,394 shares of AbbVie worth $13.2M as of Q2 2026.
- Kintegral Advisory left its AbbVie share count unchanged in Q2 2026.
- AbbVie made up 1.07% of Kintegral Advisory's portfolio in Q2 2026, its #20 holding.
- Kintegral Advisory first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Kintegral Advisory's 13F filing for Q2 2026, filed 29 Jul 2026.